Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma Journal Article


Authors: Kumar, A.; Casulo, C.; Yahalom, J.; Schöder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Jacob, A. G.; Matasar, M. J.; McArthur, G. N.; McCall, S. J.; Moskowitz, A. J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Vander Els, N.; Verwys, S. L.; Yang, J.; Younes, A.; Zelenetz, A. D.; Zhang, Z.; Moskowitz, C. H.
Article Title: Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
Abstract: This multicenter pilot study assessed the safety and efficacy of brentuximab vedotin (BV) and AVD (adriamycin, vinblastine, and dacarbazine) followed by 30 Gy involved site radiation therapy (ISRT). Patients with newly diagnosed, early stage classical Hodgkin lymphoma (HL) with unfavorable-risk features were treated with 4 cycles of BV and AVD. Patients who achieved a negative positron emission tomography (PET) scan (Deauville score of 1-3) received 30 Gy ISRT. Thirty patients received treatment and were assessable for toxicity. Twenty-nine patients completed 4 cycles of BV + AVD, and 25 patients BV + AVD + 30 Gy ISRT. No clinically significant noninfectious pneumonitis was observed. Serious adverse events(≥grade 3) were reported in 4 patients, including febrile neutropenia, peripheral neuropathy, and hypertension. After 2 and 4 cycles of BV + AVD, 90%(26 of 29) and 93%(27 or 29) of patients achieved a negative PET scan, respectively. Two patients with biopsy-proven primary refractory HL were treated off-study. All 25 patients who completed BV + AVD + ISRT achieved a complete response. With a median follow-up of 18.8 months, by intent to treat, the 1-year progression-free survival is 93.3% (95% confidence interval, 84-102). Overall, the treatment was well-tolerated with no evidence of significant pulmonary toxicity. The majority of patients (≥90%) achieved negative interim PET scans after 2 and 4 cycles of BV + AVD. Excludingthe 2 primary refractory patients, all patients are disease free, suggesting that this is a highly active treatment program even in patients with substantial disease bulk. © 2016 by The American Society of Hematology.
Journal Title: Blood
Volume: 128
Issue: 11
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2016-09-15
Start Page: 1458
End Page: 1464
Language: English
DOI: 10.1182/blood-2016-03-703470
PROVIDER: scopus
PUBMED: 27458003
PMCID: PMC5025897
DOI/URL:
Notes: Article -- Export Date: 3 October 2016 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Zhigang Zhang
    272 Zhang
  2. Joachim Yahalom
    455 Yahalom
  3. Carol Portlock
    198 Portlock
  4. Craig Moskowitz
    388 Moskowitz
  5. Ariela Noy
    225 Noy
  6. Maria Lia Palomba
    163 Palomba
  7. Steven M Horwitz
    408 Horwitz
  8. Heiko Schoder
    330 Schoder
  9. Andrew D Zelenetz
    599 Zelenetz
  10. Alison Moskowitz
    179 Moskowitz
  11. Paul Hamlin
    186 Hamlin
  12. Matthew J Matasar
    149 Matasar
  13. Philip C Caron
    41 Caron
  14. David J Straus
    245 Straus
  15. Susan J McCall
    14 McCall
  16. Anita Kumar
    67 Kumar
  17. April Chiu
    56 Chiu
  18. Alexandra G Jacob
    7 Jacob
  19. Joanna C Yang
    33 Yang
  20. Anas Younes
    246 Younes
  21. Stephanie Lisl Verwys
    4 Verwys